Cambium Bio
Biotechnology Research • Paddington, New South Wales, Australia
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair …
Reported headcount
6
Headcount reported in the resolved company record. It is independent of the number of profiles indexed by Super Carl.
Company record. Source date unavailable.
Observed active job postings
0
Active postings in the available job data. Postings may be duplicated or stale and are not a verified count of vacancies or hires.
Indexed job postings. Source date unavailable.
Reported annual revenue estimate
$670K
Annual revenue from the resolved company record; estimates may differ from filed accounts.
Company record. Source date unavailable. Estimate.
Reported total funding
$7M
Reported cumulative funding in the available company record; missing value does not mean no funding.
Company record. Source date unavailable.
Reported latest funding round
.9M
Reported amount of the latest funding round available in the company record.
Company record. Source date unavailable.
Calculated as of 2026-09-20. Source records may be older.